Search research articles
Contact Us
Filters
Showing results (111-120 of 121) with videos related to
Page
of 13
Sort By:
Leukemia & Lymphoma
|
September 25, 2019
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study
Rong Deng, Leonid Gibiansky, Tong Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2019
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
Sarina A Piha-Paul, Jasgit C Sachdev, Minal Barve, et al.
Clinical Pharmacokinetics
|
June 19, 2019
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study
Rong Deng, Leonid Gibiansky, Tong Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Anita D'Souza, Nina Shah, Cesar Rodriguez, et al.
Blood
|
August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
The Lancet. Oncology
|
November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Shaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 14, 2025
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer
Byoung Chul Cho, Melissa Johnson, Jair Bar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
Manish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 15, 2026
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
Manish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
March 6, 2009
[Rodents and rodent associated disease vectors: the network of "rodent carrying pathogens" introduces itself]
R G Ulrich, G Heckel, H-J Pelz, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 121) with videos related to
Sort By:
Page
of 13
Leukemia & Lymphoma
|
September 25, 2019
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study
Rong Deng, Leonid Gibiansky, Tong Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2019
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
Sarina A Piha-Paul, Jasgit C Sachdev, Minal Barve, et al.
Clinical Pharmacokinetics
|
June 19, 2019
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study
Rong Deng, Leonid Gibiansky, Tong Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Anita D'Souza, Nina Shah, Cesar Rodriguez, et al.
Blood
|
August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
The Lancet. Oncology
|
November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Shaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 14, 2025
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer
Byoung Chul Cho, Melissa Johnson, Jair Bar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
Manish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 15, 2026
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
Manish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
March 6, 2009
[Rodents and rodent associated disease vectors: the network of "rodent carrying pathogens" introduces itself]
R G Ulrich, G Heckel, H-J Pelz, et al.
Page
of 13